IRIS
BAGNASCO, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.431
AS - Asia 438
SA - Sud America 67
NA - Nord America 57
AF - Africa 7
Totale 8.000
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.401
SG - Singapore 181
CN - Cina 121
VN - Vietnam 95
US - Stati Uniti d'America 45
BR - Brasile 35
AR - Argentina 21
HK - Hong Kong 11
FR - Francia 10
ID - Indonesia 10
MX - Messico 10
AT - Austria 4
EC - Ecuador 4
IQ - Iraq 4
NL - Olanda 4
BD - Bangladesh 3
CL - Cile 3
IN - India 3
VE - Venezuela 3
CA - Canada 2
GB - Regno Unito 2
JP - Giappone 2
KZ - Kazakistan 2
MA - Marocco 2
RS - Serbia 2
RU - Federazione Russa 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
CY - Cipro 1
DE - Germania 1
DZ - Algeria 1
EG - Egitto 1
OM - Oman 1
PE - Perù 1
PS - Palestinian Territory 1
SE - Svezia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
UA - Ucraina 1
Totale 8.000
Salva come PNG Salva come JPEG
Città #
Genoa 3.032
Genova 2.913
Vado Ligure 733
Rapallo 675
Singapore 41
Beijing 37
Ho Chi Minh City 34
Bordighera 31
Hanoi 27
Ashburn 19
Hong Kong 11
Mexico City 6
Council Bluffs 5
Haiphong 4
San Jose 4
Tianjin 4
Biên Hòa 3
Jakarta 3
Milan 3
Ninh Bình 3
Orem 3
Bologna 2
Córdoba 2
Da Nang 2
Durban 2
Fortaleza 2
Hải Dương 2
José C. Paz 2
Montreal 2
New York 2
Querétaro 2
Quito 2
Quảng Ngãi 2
Santiago del Estero 2
Thái Bình 2
Tokyo 2
Verona 2
Vienna 2
Vĩnh Long 2
Almaty Region 1
Alvorada d'Oeste 1
Amsterdam 1
Araraquara 1
Atlanta 1
Bab Ezzouar 1
Baku 1
Bangkok 1
Barquisimeto 1
Barra do Piraí 1
Belgrade 1
Belo Horizonte 1
Bila Tserkva 1
Boa Vista 1
Boardman 1
Boca Toma 1
Brasília 1
Buenos Aires 1
Buon Ma Thuot 1
Bình Dương 1
Cabo de Santo Agostinho 1
Cairo 1
Can Tho 1
Cao Lanh 1
Chengdu 1
Chicago 1
Chongqing 1
Cibitung 1
Comodoro Rivadavia 1
Criciúma 1
Dakar 1
Dhaka 1
Divinópolis 1
Dubai 1
Erbil 1
Figueira 1
Formosa 1
Franca 1
Frankfurt am Main 1
Funes 1
Guangzhou 1
Guarulhos 1
Houston 1
Hurlingham 1
Hưng Yên 1
Ipojuca 1
Jundiaí 1
Khimki 1
Kirkuk 1
Krásno nad Kysucou 1
Las Condes 1
Lima 1
Lomas de Zamora 1
Los Angeles 1
Lucknow 1
Manaus 1
Manchester 1
Manhumirim 1
Milagro 1
Minsk 1
Mongaguá 1
Totale 7.688
Salva come PNG Salva come JPEG
Nome #
Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy 281
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 185
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 178
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma 174
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 171
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 166
Prevalence and prognostic value of cardiac troponin in elderly patients hospitalized for COVID-19 162
Personalized medicine in allergy 157
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases 156
Current insights in allergen immunotherapy 154
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 152
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 148
Biosimilars in allergic diseases 148
Impact of tDCS on persistent COVID-19 olfactory dysfunction: a double-blind sham-controlled study 148
Umeclidinium for the treatment of uncontrolled asthma 147
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 144
Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy 144
The path to personalized medicine in asthma 139
The safety of monoclonal antibodies in asthma 138
Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations 135
Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation 134
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma 133
30 Years Of Sublingual Immunotherapy 133
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 130
Update on immunotherapy for the treatment of asthma 127
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 125
Extensive activation, tissue trafficking, turnover and functional impairment of NK cells in COVID-19 patients at disease onset associates with subsequent disease severity 123
Mepolizumab in severe asthma: evidence in real-life 121
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine? 121
Multiple pulmonary nodules and unexplained fever: when the pulmonologist fails. 118
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 113
The importance of being not significant: blood eosinophils and clinical responses do not correlate in severe asthma patients treated with Mepolizumab in real life 111
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials 111
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment 103
Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study 103
Biologicals for severe asthma: what we can learn from real-life experiences? 102
One year of mepolizumab. Efficacy and safety in real-life in Italy 101
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies 99
Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy 94
Dupilumab Effectiveness in Patients with Severe Allergic Asthma Non-Responsive to Omalizumab 92
Cerebrospinal Fluid Leak Repair: Usefulness of Intrathecal Fluorescein for Correct Topographic Identification of the Skull Base Defects 86
Application of bioendoscopy filters in endoscopic assessment of sinonasal Schneiderian papillomas 85
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs 83
Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy 81
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders 80
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? 79
Minimal clinically important difference for asthma endpoints: An expert consensus report 79
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 78
Biological agents for severe asthma: the evolution of the at-home self-injection approach. 77
Quick Olfactory Sniffin’ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients 75
Anti-il5 therapies for severe eosinophilic asthma: Literature review and practical insights 75
Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy 74
Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center 68
FEV6 assessment in spirometric abnormalities screening: the first population-based study in Italian pharmacies 67
Severe asthma: One disease and multiple definitions 67
Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report 53
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 53
Severe chronic rhinosinusitis treated with dupilumab, a real-life analysis of early effectiveness 52
A case of chronic eosinophilic pneumonia in a patient treated with dupilumab 52
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 50
null 49
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 48
Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma 48
Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study 47
Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report 47
Do the current guidelines for asthma pharmacotherapy encourage over-treatment? 46
Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps 45
Specific Therapy for T2 Asthma 43
Personalizing the approach to asthma treatment 43
COPD, but Not Asthma, Is Associated with Worse Outcomes in COVID-19: Real-Life Data from Four Main Centers in Northwest Italy 42
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 42
Impulse oscillometry defined small airway dysfunction in asthmatic patients with normal spirometry: Prevalence, clinical associations, and impact on asthma control 41
Diagnostic therapeutic assistance pathway (PDTA) of type 2 chronic rhinosinusitis 41
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 40
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 40
Biologics for the Treatments of Allergic Conditions: Severe Asthma 40
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps 37
Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports 34
Real-life studies in allergen immunotherapy 33
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 32
Background therapy in severe asthma on monoclonal antibody treatment in real life 30
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 29
Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy 28
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 28
SANI clinical remission definition: a useful tool in severe asthma management 27
Strategies to reduce corticosteroid-related adverse events in asthma 27
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 25
Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach 25
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 24
New suggestions in sublingual immunotherapy for house dust mite-related allergic diseases 23
Type 2 immunity in asthma 22
Efficacy and steroid-sparing effect of benralizumab: Has it an advantage over its competitors? 21
The new indications for biologicals in type 2 diseases: perspectives 19
Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review 17
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A Analysis 13
Strategies to reduce corticosteroid-related adverse events in asthma 12
Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy? 12
COVID-19, Eosinophils, and Biologicals for Severe Asthma 11
Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85 11
Severe asthma, biologicals, and auto-injection: Yes, no, may be! 11
Totale 8.188
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.114
article - articoli 32.815
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.929
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021460 0 0 0 0 0 39 38 59 40 89 46 149
2021/2022584 19 11 17 63 14 71 23 128 53 73 14 98
2022/2023814 66 74 6 67 86 126 53 37 141 53 90 15
2023/2024701 42 81 9 79 48 177 41 42 35 13 46 88
2024/20251.966 56 133 58 137 215 214 157 302 100 98 257 239
2025/20261.688 496 129 293 208 464 98 0 0 0 0 0 0
Totale 8.238